Skip to main content
OpenTrials
Completed

NCT Number: NCT03220555

Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center

In vaccination centers, venipunctures and vaccinations are sources of pain and anxiety in pediatric patients. Prior painful experiences can reduce the acceptance of later health care, hence making it more difficult for both patients and nurses.

The topical anesthetic cream (lidocaine, prilocaine) and the non-pharmacological (distraction and relaxation) interventions which are usually used for prevention of procedural pain impose certain constraints on families and on vaccination centers.

A distraction and local anesthesia (cold and vibration) based medical device (Buzzy®) could overcome these constraints and could be an interesting alternative for healthcare management in vaccination centers and, in a broader perspective, in other medical services.

Research on this device has been scarce to date. Three of them have shown an efficacy of Buzzy® in comparison to the absence of prevention of vaccination and venipuncture induced pain. An ongoing study will assess the Buzzy® device in comparison to a topical anesthetic cream, but will be set in an emergency department context. To date, no study has compared Buzzy® to topical anesthetic cream on healthy children in a vaccination center.

The research team has formulated the following hypothesis: the Buzzy® device will allow to get a not lower or an equivalent level of pain compared to the level of pain obtained with the usual topical anesthetic cream. The aim of this study is to evaluate the efficacy of the device Buzzy® on vaccination and venipuncture induced pain in a vaccination center.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Intravenous Injections Common Cold Infections Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Picornaviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Signs and Symptoms Vaccination Virus Diseases

Age range

4 year–15 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

La Roche sur Yon University Hospital, La Roche-sur-Yon, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Any child who:

  • requires a venipuncture or a vaccination in a vaccination center
  • is 4 to 15 years old
  • is affiliated to the public social security
  • speaks French or is assisted by an translator in the language of the child
  • has given his oral consent and whose parents have given it

Exclusion criteria

Any child who:

  • suffers from sickle cell anemia
  • has a contraindication to use lidocaine patch
  • requires a Bacille de Calmette et Guérin (BCG) vaccine or tuberculin test
  • takes part in another research
  • has already participated to this study for another nursing care.
  • refused to participate or whose parents refused
  • has neurological or psychiatric disorders
  • has a nerve damage or an abrasion of the skin in terms of puncture or injection area.
  • under trusteeship or guardianship (unaccompanied foreign minors).

Treatment and study plan

Buzzy® device

Device

Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.

EMLAPATCH (lidocaine, prilocaine)

Drug

The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.

Primary outcomes

  1. Faces Pain Scale revised (FPS-r) for children

    Time frame: Day 0

    Pain will be assessed by child using the FPS-r. FPS-r is a tool which has been validated and has been shown to be reliable in intercultural children and adolescents population (4 to 17 years).

Secondary outcomes

  1. Faces Pain Scale revised (FPS-r) for parents

    Time frame: Day 0

    Pain will be assessed by a parent using the FPS-r. FPS-r is a tool which has been validated and has been shown to be reliable in intercultural children and adolescents population (4 to 17 years).

  2. Differential cost of the two strategies compared to the differential pain

    Time frame: Day 0

    Differential cost of the two strategies compared to the differential pain, self-reported by children with the FPS-r. Cost assessment of the two strategies will be made by a micro-costing analysis. The parameters analyzed will be : the strategy used (Buzzy® device or EMLAPATCH), the nurses' time and the time spent by child in the vaccination center. This parameters will be aggregated and will be presented in the form of a cost-effectiveness differential ratio and acceptability curves.

Sponsors and collaborators

Lead sponsor

Nantes University Hospital

Other

Registry information

Official study title

Efficacy of a Cold, Vibration, and Distraction Based Medical Device on the Prevention of Health Care Induced Pediatric Pain: a Comparative, Controlled, Randomized and Multicentric Study

Acronym: DOLVAX

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jul 18, 2017
Registry last updated
Sep 9, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.